MedTrace Logo

The Safety of Emicizumab SC Injection in Korean Hemophilia A Patients With/Without FVIII Inhibitors

NCT04805801 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 17

Last updated 2021-07-21

No results posted yet for this study

Summary

To evaluate Safety and efficacy and pharmacokinetics, FVIII Inhibitor titers of Hemlibra subcutaneous injection (SC inj.) in Korean Hemophilia A patients with/without FVIII Inhibitors.

Conditions

  • Hemophilia A With Inhibitor
  • Hemophilia A Without Inhibitor

Interventions

DRUG

Emicizumab subcutaneous injection

Safety and efficacy and PK, FVIII inhibitor titers will be evaluated by follow-up observation.

Sponsors & Collaborators

Principal Investigators

  • Chuhl Joo Lyu, Prof · Severance Hospital

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-28
Primary Completion
2024-07-31
Completion
2025-02-28
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04805801 on ClinicalTrials.gov